“Market withdrawals” of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations

BACKGROUND: According to the AMNOG act, the German Federal Joint Committee (G-BA) determines the additional benefit of new medicines as a basis for subsequent price negotiations. Pharmaceutical companies may withdraw their medications from the market at any time during the process. This analysis aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Staab, Thomas R., Walter, Miriam, Mariotti Nesurini, Sonja, Dintsios, Charalabos-Markos, Graf von der Schulenburg, J.-Matthias, Amelung, Volker E., Ruof, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755547/
https://www.ncbi.nlm.nih.gov/pubmed/30229501
http://dx.doi.org/10.1186/s13561-018-0209-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755547/
https://www.ncbi.nlm.nih.gov/pubmed/30229501
http://dx.doi.org/10.1186/s13561-018-0209-3

Ejemplares similares